Skye Herbals Forum
March 15, 2010, 02:19:04 AM *
Welcome, Guest. Please login or register.
Did you miss your activation email?

Login with username, password and session length
News: Let us know what you think of the new changes here on the site.  Also, feel free to post comments and questions.
 
   Home   Help Search Login Register  
Pages: [1]
  Print  
Author Topic: Silibinin causes cell cycle arrest - bladder carcinoma  (Read 5210 times)
Admin
Administrator
Sr. Member
*****
Posts: 216


WWW
« on: August 03, 2004, 12:17:42 AM »

Silibinin causes cell cycle arrest and apoptosis in human bladder transitional cell carcinoma cells by regulating CDKI-CDK-cyclin cascade, and caspase 3 and PARP cleavages.

Tyagi A, Agarwal C, Harrison G, Glode LM, Agarwal R.

Department of Pharmaceutical Sciences, School of Pharmacy, University of Colorado Health Sciences Center, Denver, CO 80262, USA.

Bladder cancer is the fourth and eighth most common cancer in men and women in the United States, respectively. Flavonoid phytochemicals are being studied for both prevent ion and therapy of various human malignancies including bladder cancer. One such naturally occurring flavonoid is silibinin isolated from milk thistle. Here, we assessed the effect of silibinin on human bladder transitional cell carcinoma (TCC) cell growth, cell cycle modulation and apoptosis induction, and associated molecular alterations, employing two different cell lines representing high-grade invasive tumor (TCC-SUP) and high-grade TCC (T-24) human bladder cancer. Silibinin treatment of these cells resulted in a significant dose- and time-dependent growth inhibition together with a G1 arrest only at lower doses in TCC-SUP cells but at both lower and higher doses in T-24 cells; higher silibinin dose showed a G2/M arrest in TCC-SUP cells. In other studies, silibinin treatment strongly induced the expression of Cip1/p21 and Kip1/p27, but resulted in a decrease in cyclin dependent kinases (CDKs) and cyclins involved in G1 progression. Silibinin treatment also showed an increased interaction between CDKIs-CDKs and a decreased CDK kinase activity. Further, the G2/M arrest by silibinin in TCC-SUP cells was associated with a decrease in pCdc25c (Ser216), Cdc25c, pCdc2 (Tyr15), Cdc2 and cyclin B1 protein levels. In additional studies, silibinin showed a dose- and a time-dependent apoptotic death only in TCC-SUP cells that was associated with cleaved forms of caspase 3 and PARP. Together, these results suggest that silibinin modulates CDKI-CDK-cyclin cascade and activates caspase 3 causing growth inhibition and apoptotic death of human TCC cells, providing a strong rationale for future studies evaluating preventive and/or intervention strategies for silibinin in bladder cancer pre-clinical models.

PMID: 15117815 [PubMed - as supplied by publisher]
Logged

Pages: [1]
  Print  
 
Jump to:  

Powered by MySQL Powered by PHP Powered by SMF 1.1.3 | SMF © 2006-2007, Simple Machines LLC Valid XHTML 1.0! Valid CSS!